In a finding that upends expectations about a widely used cancer drug, researchers in South Korea have discovered that lapatinib, an approved targeted therapy for HER2-positive breast cancer, can actually protect lung cancer cells from ferroptosis under certain conditions. The study, published in the journal Medical Oncology, shows that the drug suppresses iron-dependent cell death triggered by cysteine starvation by dialing down mitochondrial activity, even though lapatinib produces a mild ferroptotic effect when administered on its own. The work adds a striking layer of nuance to one of the hottest fields in cancer biology and carries immediate implications for how ferroptosis-targeting therapies are designed and combined.
Ferroptosis is a form of regulated cell death that has captivated oncologists since its discovery. Unlike apoptosis, the tidy, programmed dismantling of a cell, ferroptosis is a violent, iron-driven process in which reactive oxygen species attack the fatty membranes that enclose cells. Lipid peroxidation spreads like a chemical wildfire until the membrane disintegrates. Under the microscope, cells dying by ferroptosis display shrunken mitochondria with increased membrane density and diminished cristae, the internal folds where respiration takes place. Because cancer cells run metabolically hot, accumulating oxidative stress as a byproduct of their rapid growth, they are often unusually vulnerable to this mode of death, making ferroptosis an attractive therapeutic lever.
The central antioxidant defense against ferroptosis is the glutathione peroxidase 4 enzyme, or GPX4, which detoxifies phospholipid hydroperoxides using glutathione as a cofactor. Starving cells of cysteine, the amino acid required to build glutathione, collapses this defense system. Cysteine depletion does more than drain glutathione: it also impairs the synthesis of coenzyme A, disrupting lipid metabolism, and destabilizes iron-sulfur clusters, which activates an iron-starvation response that increases iron uptake through the transferrin receptor. The result is an expanding pool of unliganded ferrous iron that fuels Fenton chemistry, generating a flood of reactive oxygen species and driving lethal lipid peroxidation. A compound called RSL3 can trigger the same endpoint more directly by binding to and inhibiting GPX4 outright.
Lapatinib, meanwhile, is an orally available small-molecule inhibitor that selectively blocks the tyrosine kinase activities of the epidermal growth factor receptor EGFR and its relative HER2, suppressing the downstream MAPK and PI3K/AKT survival pathways that tumors depend on. Previous studies had painted a confusing picture of its relationship with ferroptosis. In breast cancer cells, lapatinib promoted ferroptosis when combined with a lysosome-disrupting agent, accompanied by iron accumulation. More recently, it was reported to induce ferroptosis in osteosarcoma by disrupting glutamine uptake and glutathione synthesis. Yet in neuronal cells, lapatinib was found to suppress ferroptosis by restoring GPX4 expression. The new study set out to resolve how the drug behaves when ferroptosis is induced by cysteine deprivation in non-small cell lung cancer cells.
The research team, led by investigators at the Korea Institute of Radiological and Medical Sciences and collaborating institutions, worked with two human lung cancer cell lines, H1299 and H23. When the cells were deprived of cysteine for 24 hours, viability in H1299 cells collapsed to roughly 30 percent of control levels. Remarkably, adding lapatinib restored viability in a dose-dependent manner, climbing back to about 65 percent at a concentration of 10 micromolar. In H23 cells, where cysteine deprivation cut viability to about a quarter of normal, lapatinib again rescued the cells dose-dependently. Crucially, two other EGFR-targeting drugs, erlotinib and gefitinib, offered no such protection, indicating that the effect is not a generic property of this drug class.
To confirm that the cell death in question was truly ferroptosis, the researchers deployed a panel of benchmark compounds. Ferrostatin-1 and liproxstatin-1, both inhibitors of lipid peroxidation, and deferoxamine, an iron chelator, all significantly blunted the viability loss caused by cysteine deprivation, whereas z-VAD-fmk, an apoptosis blocker, had no effect. That pharmacological fingerprint pointed squarely at ferroptosis. The team then measured malondialdehyde, a major end product of lipid peroxidation, and used the C11-BODIPY fluorescent probe to visualize membrane oxidation directly. Cysteine deprivation drove both markers sharply upward, and lapatinib pulled them back down in both cell lines, confirming that the drug was suppressing the lipid peroxidation cascade at its core.
The mechanistic surprises deepened from there. Cysteine deprivation and lapatinib each independently raised intracellular reactive oxygen species and ferrous iron levels when given alone. Yet when lapatinib was combined with cysteine deprivation, it significantly reduced ROS generation even though intracellular ferrous iron remained elevated, comparable to levels seen with lapatinib alone. Even more counterintuitively, lapatinib further depleted glutathione and further reduced GPX4 protein expression under cysteine-deprived conditions, the opposite of what a ferroptosis-suppressing intervention would be expected to do through the canonical antioxidant pathway. The drug also protected cells from RSL3, the direct GPX4 inhibitor, while again lowering GPX4 expression further, demonstrating that its protective effect operates entirely independently of the glutathione-GPX4 axis.
The answer, the researchers found, lies in the mitochondria. Both cysteine deprivation and RSL3 treatment caused hyperpolarization of the mitochondrial membrane potential, detected by increased TMRE fluorescence, along with a marked rise in oxygen consumption, signatures of revved-up mitochondrial metabolism that have previously been linked to mitochondrial ROS generation and ferroptotic death. Lapatinib alone produced only modest increases in these parameters, but when co-administered with either ferroptotic stimulus, it significantly blunted both the membrane hyperpolarization and the surge in oxygen consumption. By restraining excessive mitochondrial metabolic activation, lapatinib appears to cut off the supply of mitochondrial ROS that sustains lipid peroxidation, rendering the accumulated ferrous iron insufficient to keep the ferroptotic fire burning.
Why would lapatinib calm mitochondrial respiration? The authors point to a tantalizing clue from a recent computational study predicting that lapatinib interacts with SLC1A5, a glutamine transporter. Glutaminolysis, the conversion of glutamine into alpha-ketoglutarate that feeds the tricarboxylic acid cycle, is indispensable for cysteine deprivation-induced ferroptosis, because it supplies the mitochondrial fuel that drives the respiratory surge. If lapatinib disrupts glutamine metabolism, reduced glutaminolysis would dampen mitochondrial activation and thereby limit ROS generation, a hypothesis consistent with the team’s observations. The precise molecular mechanism, however, remains to be worked out, and the researchers are careful to frame this as a hypothesis rather than a settled explanation.
The therapeutic implications cut in an uncomfortable direction. Ferroptosis induction is increasingly viewed as a way to overcome resistance to conventional agents such as cisplatin, docetaxel and sorafenib, and to amplify the effects of chemotherapy, radiotherapy and immunotherapy. If lapatinib suppresses ferroptosis that depends on mitochondrial metabolic activation, then combining it with such strategies could inadvertently blunt their efficacy and contribute to therapeutic resistance. The study also reinforces a broader lesson now echoing through the ferroptosis field: drug effects on this cell death pathway are exquisitely context-dependent, shaped by cell type, metabolic state and the specific trigger involved. A drug that kills by ferroptosis in one setting may protect against it in another, and clinicians designing rational combinations will need to account for that metabolic fine print.
Subject of Research: Context-dependent regulation of ferroptotic cell death by the EGFR/HER2 inhibitor lapatinib in non-small cell lung cancer cells
Article Title: Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function
Article References: Kim, G., Jang, S.-K., Kim, D.-G., Kim, H., Hong, J., Park, I.-C., & Jin, H.-O. (2026). Lapatinib suppresses cysteine deprivation-induced ferroptotic cell death by modulating mitochondrial function. Medical Oncology, 43(11), Article 294. https://doi.org/10.1007/s12032-026-03402-7
Image Credits: AI Generated
DOI: 10.1007/s12032-026-03402-7
Keywords: lapatinib, ferroptosis, cysteine deprivation, mitochondria, GPX4, glutathione, lipid peroxidation, reactive oxygen species, non-small cell lung cancer, EGFR inhibitors, RSL3, mitochondrial membrane potential
Cite Scienmag News
APA
MLA
Chicago
Nathaniel Bowman. (October 1, 2026). Breast Cancer Drug Lapatinib Unexpectedly Shields Lung Cancer Cells From Ferroptosis. Scienmag. https://scienmag.com/breast-cancer-drug-lapatinib-unexpectedly-shields-lung-cancer-cells-from-ferroptosis/
Nathaniel Bowman. “Breast Cancer Drug Lapatinib Unexpectedly Shields Lung Cancer Cells From Ferroptosis.” Scienmag, 1 October 2026, https://scienmag.com/breast-cancer-drug-lapatinib-unexpectedly-shields-lung-cancer-cells-from-ferroptosis/. Accessed 1 October 2026.
Nathaniel Bowman. “Breast Cancer Drug Lapatinib Unexpectedly Shields Lung Cancer Cells From Ferroptosis.” Scienmag. October 1, 2026. https://scienmag.com/breast-cancer-drug-lapatinib-unexpectedly-shields-lung-cancer-cells-from-ferroptosis/
Copy citation
Download RIS
Tags: breast cancer targeted therapycancer cell metabolic vulnerabilitiescysteine deprivationdesign of ferroptosis-targeting cancer therapiesdrug resistance in cancer therapyEGFR inhibitorsferroptosisferroptosis in cancer treatment strategiesglutathioneGPX4HER2-positive breast cancer drug effectsimpact of cysteine starvation on cancer cellsiron-dependent cell death mechanismslapatiniblapatinib and ferroptosis in lung cancer cellslipid peroxidationlipid peroxidation in ferroptosismitochondriamitochondrial activity modulation by targeted drugsmitochondrial membrane potentialnon-small cell lung cancerreactive oxygen speciesRSL3unintended drug effects on lung cancer
